Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

No­var­tis will pay $150 mil­lion up­front to Schrödinger, in a pact an­nounced Tues­day to work to­geth­er on sev­er­al ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...

A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...

Trace Neu­ro­science, a start­up spun out of Maze Ther­a­peu­tics’ pipeline, broke cov­er Tues­day morn­ing with $101 ...

Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, ...

Bay­er re­it­er­at­ed its plans to ride out the gener­ic-dri­ven sales de­cline of its throm­bo­sis drug Xarel­to, as the ...

Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...